Ana Laura de Souza Almeida Matos

Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial

Chantal Mathieu, Björg Ásbjörnsdóttir, Harpreet S. Bajaj et al. · The Lancet · 2023 · 130 citations

Diabetes Management, Insulin Management, Diabetes +7

Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial

Steven E. Kahn, John Deanfield, Ole Kleist Jeppesen et al. · Diabetes Care · 2024 · 61 citations · Full text

The Effect of Semaglutide on Mortality and COVID-19–Related Deaths

Benjamin M. Scirica, A. Michael Lincoff, Ildiko Lingvay et al. · Journal of the American College of Cardiology · 2024 · 39 citations · Full text

Co-expression of TIMP-1 and its cell surface binding partner CD63 in glioblastomas

Charlotte Aaberg-Jessen, Mia Dahl Sørensen, Ana Laura de Souza Almeida Matos et al. · BMC Cancer · 2018 · 37 citations · Full text

Metallopeptidase inhibitor 1 (TIMP‐1) promotes receptor tyrosine kinase c‐Kit signaling in colorectal cancer

Cathrine Nordgaard, Sophia Doll, Ana Laura de Souza Almeida Matos et al. · Molecular Oncology · 2019 · 11 citations · Full text